Smell Loss Predicts Mortality Irrespective of Dementia

This article originally appeared here.
Share this content:
Smell Loss Predicts Mortality Irrespective of Dementia
Smell Loss Predicts Mortality Irrespective of Dementia

FRIDAY, March 24, 2017 (HealthDay News) -- Poor odor identification and poor self-reported olfactory function are associated with greater likelihood of earlier mortality, according to a study published online March 22 in the Journal of the American Geriatrics Society.

In a population-based cohort of 1,774 dementia-free adults aged 40 to 90 years, Ingrid Ekström, from Stockholm University, and colleagues assessed olfactory performance using the Scandinavian Odor-Identification Test (SOIT) and self-reported olfactory function. Additionally, several social, cognitive, and medical risk factors were evaluated at baseline, while incident dementia was calculated over a decade of follow-up.

Over the 10-year study period, 411 of 1,774 participants died. The researchers observed a significant association between higher SOIT score and lower mortality (hazard ratio, 0.74 per point interval). After controlling for age, sex, education, and health-related and cognitive variables, the effect was lessened but remained significant (hazard ratio, 0.92). Furthermore, the association between SOIT score and mortality was retained after controlling for dementia conversion before death (hazard ratio, 0.92). Similar results were seen for self-reported olfactory dysfunction.

"Dementia does not attenuate the association between olfactory loss and mortality, suggesting that olfactory loss might mark deteriorating health, irrespective of dementia," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Incident Contrast Sensitivity Common in Middle-Aged Adults

Incident Contrast Sensitivity Common in Middle-Aged Adults

Factors linked to elevated risk include cadmium level in highest quintile, older age, more plaque sites

Tafamidis Treats Transthyretin Amyloid Cardiomyopathy

Tafamidis Treats Transthyretin Amyloid Cardiomyopathy

Reduces all-cause mortality, cardiovascular-related hospitalizations compared with placebo

Scribes Improve Physician Workflow, Patient Interaction

Scribes Improve Physician Workflow, Patient Interaction

Scribes lower EHR documentation burden for doctors and increase time spent interacting with patients

is free, fast, and customized just for you!




Already a member?

Sign In Now »